CSL Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares CSL Limited with three other
pharmaceutical manufacturers in Australasia:
sales of 107.22 million Australian Dollars [US$75.88 million]
AFT Pharmaceuticals Ltd
of NEW ZEALAND
(105.60 million New Zealand Dollars [US$69.15 million]
of which 58%
was Australia), and
Mayne Pharma Group Limited
(457.77 million Australian Dollars [US$323.97 million]
of which 55%
was Generic Products).
CSL Limited reported sales of A$13.65 billion (US$9.66 billion)
June of 2020.
increase of 14.3%
versus 2019, when the company's sales were A$11.95 billion.
Sales at CSL Limited have increased during each of the previous five years
(and since 2015, sales have increased a total of 101%).
Sales of Seqirus saw an increase
18.9% in 2020, from
A$1.42 billion to A$1.69 billion.